Global Cyclodextrins In Pharma Market
市场规模（十亿美元）
CAGR :
% 
USD
316.32 Million
USD
432.90 Million
2025
2033
 Forecast Period |
2026 –2033 |
 Market Size (Base Year) |
USD 316.32 Million |
 Market Size (Forecast Year) |
USD 432.90 Million |
 CAGR |
% |
| Major Markets Players |
|
医药市场中的全球摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-摇篮-),结构(摇篮-摇篮-摇篮-摇篮-摇篮-摇
医药市场上的环形花序概览
医药市场中的环形花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花.2025年3.1632亿美元预计将达到截至2033年的43290万美元,生长在一个2026年至2033年的CAGR为4.00%.市场正在稳步增长,其驱动力是日益采用环丁二醇作为先进药物配方的引出物,对提高水溶性差的药物溶解性的需求不断增加,以及在受管制和有针对性的药物提供系统中扩大使用。
日益重视提高活性药物成分的生物利用率和稳定性,加上配方科学的迅速进步和以纳米技术为基础的药物的提供,大大地推动了整个制药业使用环丁二醇。 此外,制药公司增加研发投资,同时扩大口服、注射和局部药物配方的应用,进一步支持了市场扩张,特别是在新疗法和复杂分子开发方面。
主要市场趋势和见解
- 北美在Pharma市场主导了Cyclodexrins,2025年收入份额最大,为36.28%,辅以强大的药物研发活动,高水平采用先进的药物提供系统,以及主要的特产外卖制造商.
- 2-Hydroxypropyl-β-Cyclodexrin部分在2025年以38.47%的比重带动了市场,其驱动力在于其优越的溶解能力,安全性能得到提高,注射用药和口服用药配方得到广泛的监管接受.
- 亚太区域预计将是增长最快的区域,2026年至2033年的CAGR增长率为6.9%,而中国、印度和韩国则通过扩大非专利药品生产、增加药品研发投资以及不断增长的保健基础设施来推动这一增长。
- 硫磺酰基β-环己醇是增长最快的一种,预计CAGR为6.8%,反映了对加强安全特征和注射用药的高级复合效率的需求激增。
- 2025年Cyclodexrin Conjugates分部以35.62%的收入份额在结构类别中占了主导地位,其主导地位是它们具有强大的化学能力,能够与活性药物成分相接,以提高稳定性和控制性释放.
- 氢化物占市场的57.84%,因为水溶性差的药物广泛用于提高溶解性和生物利用率。
- 液分是增长最快的形态类,CAGR为7.0%,受注射和静脉注射制剂需求增加所驱动.
市场大小和预测
- 全球市场价值(2025):3.1632亿美元
- 预期市场价值(2033):432.90万美元
- CAGR预测(2026-2033):4.00%
- 2025年主要区域:北美
- 快速增长区域:亚太
《医药市场的范围和环形化合物报告》分块
|
属性 |
药用钥匙中的旋律外观市场透视 |
|
覆盖部分 |
|
|
涵盖国家 |
北美 · 美国。 加拿大 墨西哥 欧洲 德国 法国 英国。 荷兰 瑞士 比利时 · 俄罗斯 · 意大利 • 西班牙 土耳其 · 欧洲其他地区 亚太 中国 * 日本 • 印度 韩国 新加坡 马来西亚 澳大利亚 泰国 印度尼西亚 菲律宾 亚太其他地区 中东和非洲 沙特阿拉伯 · 美国 南非 • 埃及 • 以色列 中东其他地区和非洲 南美洲 • 巴西 阿根廷 南美洲其他地区 |
|
关键市场玩家 |
• 妇女贝克·切米集团(德国) • 妇女罗克特·弗雷斯(法国) • 妇女阿什兰公司(美国). • 妇女默克 KGaA(德国) • 妇女利干制药公司(美国). * CycloLab Cyclodelexrin研究与发展实验室有限公司(匈牙利) BASF SE(德国) · 道公司(美国) · 国际火焰和花纹公司(美国) · 辉瑞公司(美国) 萨诺菲(法国) · 东京化学工业有限公司(日本) • Cargill公司(美国) · 山东辛达生物技术有限公司(中国) · 江苏风云生物工程有限公司(中国) - 西安德利生化工业有限公司(中国) · 山东宾州志远生物技术有限公司(中国) · WELDING GmbH & Co. KG(德国) * 瑟莫·费舍尔科学公司(美国) ● 山东Q水生物科技有限公司(中国) |
|
市场机会 |
· 对生物学中溶解性增强的释放物和水溶性差的活化物的需求增加 · 扩大在有针对性和有控制的药物运载系统中使用环二甲苯 · 为稳定敏感分子,越来越多地采用亲和(可注射)配方中的环丁二醇 |
|
添加数据信息集的值 |
除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。 |
医药市场趋势中的旋律
趋势:扩大先进药物提供和配制技术
制药公司正在越来越多地采用环丁二醇来提高口服、可注射和热门制剂中不易溶于水的药物的溶解性、稳定性和生物利用率。 向复杂分子,包括生物学和脂原API的日益转变,正在加速对纳入复合物的需求,这些复合物可以提高药物的性能而不会改变治疗效果。 以纳米技术为基础的运载系统和可控放行配方的持续创新,正在进一步加强环十二烷在下一代药物开发平台中的作用。 例如,可注射的异丙烯酸和其他抗活性制剂越来越多地使用羟基丙基-β-环己二醇来提高水溶性和临床可用性。
医药市场动态中的环链外激素
主要市场驱动力:对溶解性增强的需求增加
低溶性活性药物成份的日益流行,极大地推动了将环丁二醇作为现代药物配方的放活剂。 制药厂家日益依赖环丁二醇复合物来提高吸收率,提高生物利用率,并确保在通用和创新性药物管道中取得一致的治疗结果。 这一需求通过扩大研发投资而得到进一步加强,这些投资侧重于重新调整现有药物,并通过更有效的剂量形式提高患者的合规性。 例如,广泛使用以环脱氧核糖核酸为基础的抗癌和抗风药的活化剂来提高静脉注射效率并减少对毒性的关切。
关键限制/挑战:药品-螺旋外接剂的成本高和监管复杂
药用市场中环十二氯丁二烯的一个主要制约因素是生产成本高和与医药级分泌物,特别是经修改的环十二氯丁二烯有关的严格监管要求. 达到可注射和高纯度口服制剂标准所需的净化工艺大大增加了制造的复杂性和总体成本,限制了价格敏感的非专利药品生产商的采用。 此外,不同区域不同的监管审批也为大规模商业化制造了障碍并减缓了产品开发周期. 例如,在母体应用中围绕β-环丁二烯衍生物进行的监管审查导致若干国际市场延长了批准时限。
主要市场机会:扩大定向药品交付和新疗法应用
日益重视精密医学和先进的药物提供系统,正在为在肿瘤、神经和罕见疾病治疗的定向和控制下释放配方中的环丁二醇创造很大机会。 它们能够与疏水药物形成融合复合体,能够改进具体地点的投放,降低毒性并增强治疗效率,使它们非常适合下一代特有药物。 在重新制定现有药物和扶持新的分子实体方面日益被采用,这正在进一步扩大品牌制药和通用制药部门的商业潜力。 例如,在抗癌药物运载系统中,正越来越多地探索以环乙二醇为基体的复合物,例如和平克氏剂,以提高溶解性并减少与制剂有关的不良反应。
医药市场范围内的自行车
药用市场上的环丁二烯根据类型,结构,性质,形式,应用,治疗领域,以及分配渠道进行分解.
- 按类型
根据类型,医药市场中环形花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序花序 2-Hydroxypropyl-β-Cyclodexrin部分在2025年占了38.47%的市场份额,因为其溶解能力优越,安全情况有所改善,注射用药和口服药配方的管制范围广泛。 它被广泛用于抗风、抗癌和心血管药物,以提高低溶性API的生物利用率。 与水合物和脂合物的强烈相容性使其在药物应用方面具有高度多能性。 它既有的临床用途和商业可用性进一步加强了它在全球市场中的支配地位。 越来越多地采用从头到尾的表述继续加强其领导地位。
2026年至2033年,由于注射药物安全性能得到提高并具有较高的复合效率,预计硫磺酰β-环氧基苯丙胺的CAGR增长最快,为6.8%。 由于毒性低和水溶性能高,它被广泛用于亲和配方. 对高级注射疗法的需求日益增加,特别是在肿瘤学和关键护理方面。 制药公司越来越多地将其用于现有药物的再配制,以提高稳定性并减少副作用. 新药应用的监管审批进一步支撑了市场渗透. 扩大生物学和特产药物管道也正在推动对这一衍生物的需求。
- 按结构
以结构为基础,将市场分解为:环克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克特克. Cyclodexrin Conjugates部分在2025年占据了35.62%的市场份额,其驱动力在于它们具有强大的化学能力与活性药物成分相接,以提高稳定性和控制性释放. 这些组合提高了药物靶向效率并减少了生物环境中的降解. 它们被广泛用于肿瘤学和慢性病治疗,因为持续释放至关重要。 在先进的药物提供系统中增加研发活动将进一步支持其采用。 它们提高药效动力学的能力,使得它们在新药配方中具有很高的价值. 专利药物技术的强大存在加强了它们的市场领导力。
Amphiphilic Cyclodexrins分片预计在2026年至2033年7.1%的CAGR中是生长最快的,因为它们具有与水生和脂生药物分子相互作用的独特能力. 这种双重亲和性使膜可渗透性和有针对性地提供药物成为可能。 它们越来越多地被纳米医疗和先进的治疗系统所使用. 日益重视精密医学和细胞内药物的提供正驱动着需求. 癌症和神经治疗药物创新正在加速采用。 对以纳米技术为基础的药物载体的投资不断增加,进一步支持了部分的增长。
- 按性质
根据自然因素,市场被分解成水生和疏水生环丁基。 2025年,Hydrophilic部分在市场上占有57.84%的份额,因为它广泛用于提高溶水性差的药物的溶解性和生物利用率。 在口服和可注射配方中,氢化环丁二烯由于与水系的极佳相容性而得到高度偏好. 它们在提高药物溶解率和吸收效率方面发挥关键作用。 它们的安全情况和管理接受进一步支持了广泛的药物使用。 对液态和可注射制剂的需求不断增加,这继续强化这一环节。 大力利用非专利和品牌药物制造加强了其支配地位。
2026至2033年的CAGR为6.6%,由于控制下释放和有针对性地提供药物系统使用量的增加,预计疏水部分增长最快。 以脂质为基础的持续放出配方中,这些环丁二烯正获得牵引力。 他们封装疏水药物的能力提高了稳定性和治疗效率. 越来越多的癌症和CNS药物提供研究正在推动收养。 改进后环丁二烯化学的进步进一步提高了性能. 扩大专科治疗的应用正在加速分化增长。
- 按表单
根据形式,市场被分割成固体和液体. 固体部分在2025年以64.18%的比重占据了市场主导地位,其动力是易于处理,保存寿命长,并被广泛用于平板和胶囊配方. 由于稳定性和成本效益,在大规模制药制造中更倾向于固态环丙二醇. 它们被广泛用于口服固体剂量形式来提高药物溶解性. 与干燥混合和颗粒过程的强烈相容性支持了它们的主导地位. 增加非专利固体剂量药物的生产进一步加强了这一环节。 制药制造业的可扩展性继续加强其领导作用。
由于对可注射和静脉注射制剂的需求不断增加,预计液体部分在2026年至2033年7.0%的CAGR增长最快。 液环脱氧酯被广泛用于需要快速提供药物的医院治疗. 它们为制定不稳定或溶解性差的API提供了更好的灵活性。 在关键护理和肿瘤治疗方面越来越多的收养正在增加需求。 无菌制剂技术的进步进一步支撑了增长。 扩大生物学和母体药物管道正在加速分支扩张。
- 通过应用程序
根据应用情况,市场分为药物溶解和溶解、药物生物利用率、药物安全、药物稳定性等。 药物溶解和溶解部分在2025年占据了41.76%的市场主导地位,其驱动力是日益需要改善水溶性差的药物的性能。 环形花序素被广泛用于形成能提高溶解率和吸收的包含复合体. 制药公司在新的药物开发和再配制战略中严重依赖这种应用。 药物管道中溶解性差的API的日益普遍增加了需求。 严格地通过口头和注射方式强化了支配地位。 不断创新溶性增强技术,支持市场引导.
药物生物利用率部分预计在2026年至2033年6.9%的CAGR增长最快,其动力是更加注重提高现有药物的治疗效率。 环球激素有助于增强系统吸收并降低剂量需要. 日益强调病人遵守规定和减少副作用正在推动收养。 制药研发越来越多地将生物利用率优化作为重塑的目标。 扩大肿瘤学和CNS药物的使用进一步支持了增长。 纳米载体系统的进展正在加速扩展。
- 治疗区
在治疗领域的基础上,市场被划分为疼痛管理,心血管疾病,行为失常,癌症治疗,风湿性关节炎,癫痫,尼曼-皮克疾病C型(NPC)等. 癌症治疗部分在2025年占据了39.28%的市场份额,其驱动力是大量使用环氯丁二烯来溶解和提供抗癌药物。 由于溶解性差,许多化疗剂需要配方增强. 在癌症治疗中,环球素能提高药物稳定性并降低毒性. 全球癌症负担日益加重,这进一步加强了需求。 强有力的肿瘤药物管道支持继续占主导地位。 定向癌症疗法的药品创新加强了这一部分。
尼曼-皮克疾病C型(NPC)部分预计在2026至2033年的CAGR7.3%中增长最快,其驱动力是稀有疾病治疗中越来越多地使用环丙二醇类疗法. 正在积极研究NPC管理方面的胆固醇-清除特性。 越来越多的孤儿药物发展方案正在支持研究和收养。 罕见病治疗监管激励机制加快创新. 越来越多的临床试验正在扩大治疗应用。 强烈的未得到满足的医疗需要正在推动迅速增长。
- 按发行频道
以发售渠道为基础,将市场分割成直接招标,零售等环节. 2025年,在制药公司、医院和研究机构大宗采购的推动下,直接招标部分占了市场的61.43%的份额。 该信道确保高纯度环丁烷的成本效益和持续供应。 制造商与大型买方之间的牢固关系支持支配地位。 它被广泛用于机构和政府保健采购系统。 制药生产设施需求的增加进一步加强了这一部门。 可靠的供应链协定加强了其领导地位。
零售销售部分预计在2026至2033年的7.2%的CAGR增长最快,因为经销商和化学品供应商的特快产品越来越多。 小型和中型制药公司越来越多地通过零售渠道采购。 研究实验室和学术机构日益增长的需求正在推动采用。 扩大在线化工配送平台进一步支撑增长. 灵活性和较低的进入壁垒使这一通道具有吸引力。 全球研发活动不断增加,继续加速扩大。
医药市场区域分析中的自行车
北美在Pharma市场主导了Cyclodexrins,2025年收入份额最大,为36.28%,辅以强大的药物研发活动,高水平采用先进的药物提供系统,以及主要的特产外卖制造商. 本区域还得益于大量采用创新的药物提供系统,广泛使用环丁二醇来进行可注射和口服配方,以及建立完善的监管框架,支持快速创新。 增加溶解性需求,加强水溶性差的药物,并大力投资于肿瘤学和专科治疗,继续加强北美在全球市场上的领导作用。
医药市场透视中的美国环球外观
由于对先进药物配方技术的投资不断增加,在专科治疗方面研发的扩大,对溶解性增强解决方案的需求也日益增加,美国药市的环丁香正在出现强劲增长。 国内发达的制药业,以及广泛采用可注射、口服和肿瘤药物制剂中的环丁二醇,正在推动整个商业和临床应用的市场扩张。 此外,日益重视生物学发展、精密医学和现有药物的再配制,正在加速药物制造商和研究机构采用环十二氯丁二烯。
医药市场透视中的欧洲旋律外观
药用市场上的欧洲百科全书仍然是全球收入的一个主要贡献,其驱动力是:对快速创新提供强有力的监管支持、先进的制药制造能力以及对改进药物提供系统的高需求。 在可注射和可控制放出制剂中广泛使用环十二氯丁二烯正支持整个肿瘤、心血管和特有药物部分的市场扩张。 增加药品研发投资,加上严格的质量标准和高度发达的医疗保健系统,继续推动全欧洲采用环丁香。
英国Cyclodexrins in Pharma 市场透视
英国药用市场上的环丙二醇正稳步增长,药物配方中先进出剂的采用率不断上升,药物研发活动强劲,对罕见疾病疗法的关注也日益突出。 对提高生物利用率和药物稳定性的需求日益增加,有助于在口服和可注射制剂中更广泛地使用环丁二醇。 此外,融合创新的药物提供技术并扩展临床研究活动,正在将英国定位为制药业百科全书的重要创新中心.
医药市场透视中的德国自行车
德国制药市场的百科全书正在稳步扩张,这要归功于德国强大的医药制造基础、先进的化学专业知识以及越来越多的高性能的外出药。 制药公司和研究机构正越来越多地利用环丁二烯来提高复杂药物分子的可溶性、稳定性和安全性。 配方科学的持续进步,加上强有力的监管标准和对高质量药物发展的关注,进一步推动了德国的市场增长.
医药市场透视中的亚太环球外观
药用市场上的亚太环十二烷预计会迅速增长,其驱动力是扩大制药生产,增加非专利药物制造,以及中国、印度和日本等国家对保健基础设施的投资增加。 人们对先进药物提供系统的认识日益提高,慢性疾病的发病率不断上升,以及越来越多地采用配方强化剂,这些都支持了区域市场的扩大。 此外,不断增长的药物研发活动和合同制造能力正在加速整个商业和临床部门采用环丁二醇。
日本医药市场透视中的旋律外观
由于对先进药物提供技术的投资不断增加,药物创新强劲,对稀有和慢性疾病治疗的关注也日益突出,因此日本制药市场中的环丁香正在持续增长。 制药公司和研究机构越来越多地采用环丁二醇来提高药物在复杂配方中的可溶性和稳定性. 此外,高精度配方技术日益融合,并大力强调病人的安全和治疗效率,进一步推动了日本的市场增长。
医药市场透视中的中国自行车
药用市场上的"中国百科全书"在扩大制药制造业,加大药品研发投资等推动下快速发展,更加注重提高药品生物利用率. 国内制药公司越来越多地采用先进配方技术,大大推动了对环丁二醇的需求。 此外,慢性病发病率不断上升,政府大力支持保健创新,并迅速扩大非专利和特有药品生产,使中国成为全球增长最快的市场之一。
药品市场份额中的环形花序
药用工业中的环丁香主要由地位良好的公司主导,包括:
- 贝克·切米·AG(德国)
- 罗克特·弗雷斯(法国)
- Ashland Inc. (美国)
- 默克·克加阿(德国)
- 利干制药公司(美国)
- CycloLab Cyclodextrin研发实验室有限公司(匈牙利)
- BASF SE(德国)
- 道氏股份有限公司 (美国).
- 国际Flavors & Fragrances Inc. (美国).
- 辉瑞股份有限公司(美国)
- 萨诺菲(法国)
- 东京化学工业有限公司(日本)
- 卡吉尔公司(美国)
- 山东新田生物技术有限公司(中国).
- 江苏风云生物工程有限公司(中国).
- 西安德利生化工业有限公司(中国)
- 山东滨州志远生物技术有限公司(中国).
- (德国)
- 瑟莫·费舍尔科学公司(美国)
- 山东Q水生物科技有限公司(中国).
医药市场环形外观的最新发展
- 2026年5月,关于对Niemann-Pick C型疾病进行以环脱氧酯为基础的调查疗法 -- -- adrabetadex的监管更新,突出了正在进行的FDA审查过程以及批准以环脱氧酯为基础的罕见疾病治疗的复杂性。 发展重点强调先进临床管线中由环丁二烯驱动的药物的治疗潜力和监管挑战
- 2025年10月,林业发展局批准了由Captisol-United配方(Lasix ONYU),这标志着在以环丁二醇为原料的药物交付方面取得重大进展,特别是使用磺丁基-β-环丁二醇(SBECD)来增强心脏衰竭治疗注射疗法的溶解性和稳定性。 这一发展加强了对母体药物配方中环丁二氧激素排出物的监管接受,并扩大了它们在医院疗法中的使用
- 2025年5月,一项科学审查强调,环丁二醇作为药物释放剂和潜在活性治疗剂的作用正在扩大,特别是在胆固醇调制、抗病毒疗法和罕见疾病治疗等应用方面。 该研究突出了研发对环十二氯丁二烯融合复合体的日益浓厚的兴趣及其在先进药物提供系统中不断演变的作用。
- 2025年4月,孤儿药物管道的发展显示肿瘤学和罕见疾病治疗方案越来越多地使用环丁二氧化合物,反映出工业界日益重视改善药物稳定性和治疗针对性。 这一转变凸显出以环丁二醇为原料的配方在特殊药品中的商业相关性正在扩大。
- 2024年2月,科学研究突出强调了以环丁二氧为原料的药物提供系统的重大进步,强调它们在改善溶解性,溶解性,以及水溶性差的药物的生物利用率等方面发挥越来越大的作用. 该研究报告在可注射和口服配方中更广泛地采用HP-β-CD和SBECD等经过修改的环十二烷,这反映了配方在科学创新方面的强劲增长。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 THERAPEUTIC AREAS LIFELINE CURVE
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATIONS
5.1 FDA
5.2 JAPAN
6 IMPACT OF COVID-19 ON GLOBAL CYCLODEXTRIN IN PHARMA MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS
7.1.2 INCREASING DRUG STABILITY
7.1.3 USE OF CYCLODEXTRIN IN DRUG DELIVERY
7.1.4 LAUNCH OF FINISHED PRODUCTS OF CYCLODEXTRIN
7.1.5 RISING PREVALENCE OF CHRONIC DISEASES
7.2 RESTRAINTS
7.2.1 HIGH COSTS OF CYCLODEXTRIN
7.2.2 TOXICITY STUDIES OF CYCLODEXTRINS
7.3 OPPORTUNITIES
7.3.1 INCREASING RESEARCH OF CYCLODEXTRIN IN COVID-19 TREATMENT
7.3.2 RISING USE OF CYCLODEXTRIN IN RENAL DISEASES
7.3.3 RISING INVESTMENT ON RESEARCH ACTIVITIES
7.3.4 INCREASES AWARENESS ABOUT THE USE OF CYCLODEXTRIN IN PHARMA INDUSTRY
7.4 CHALLENGES
7.4.1 LIMITATION OF CYCLODEXTRIN IN OPTHALMIC USE
7.4.2 USE OF VARIOUS TECHNIQUES IN MANUFACTURING CYCLODEXTRIN
8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE
8.1 OVERVIEW
8.1.1 Β CYCLODEXTRIN
8.1.2 2-HYDROXYPROPYL-Β-CYCLODEXTRIN
8.1.3 Α CYCLODEXTRIN
8.1.4 Γ-CYCLODEXTRIN
8.1.5 RANDOMLY METHYLATED Β-CYCLODEXTRIN
8.1.6 SULFOBUTYLETHER Β-CYCLODEXTRIN
8.1.7 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN
9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE
9.1 OVERVIEW
9.2 CYCLODEXTRIN CONJUGATES
9.2.1 POLYMERS
9.2.2 NANOSPONGES
9.3 MUCOADHESIVE DRUG CARRIERS
9.3.1 POLYETHYLENE-GLYCOL
9.3.2 CHITOSAN
9.3.3 ALGINATE
9.4 CYCLODEXTRIN ASSOCIATES
9.4.1 POLYPSEUDOROTAXANES
9.4.2 POLYROTAXANES
9.5 AMPHIPHILIC CYCLODEXTRINS
9.5.1 POLYSUBSTITUTED
9.5.2 MONOSUBSTITUTED
9.6 OTHERS
10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM
10.1 OVERVIEW
10.2 SOLID
10.3 LIQUID
11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE
11.1 OVERVIEW
11.2 HYDROPHILIC
11.3 HYDROPHOBIC
12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DRUG SOLUBILITY AND DISSOLUTION
12.3 DRUG BIOAVAILABILITY
12.4 DRUG SAFETY
12.5 DRUG STABILITY
12.6 OTHERS
13 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS
13.1 OVERVIEW
13.2 PAIN MANAGEMENT
13.3 CARDIOVASCULAR DISEASES
13.4 BEHAVIORAL DISORDER
13.5 CANCER THERAPY
13.6 RHEUMATOID ARTHRITIS
13.7 EPILEPSY
13.8 NIEMANN PICK DISEASE TYPE C (NPC)
13.9 OTHERS
14 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.4 OTHERS
15 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY GEOGRAPHY
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K
15.3.4 ITALY
15.3.5 NETHERLANDS
15.3.6 SPAIN
15.3.7 RUSSIA
15.3.8 SWITZERLAND
15.3.9 BELGIUM
15.3.10 TURKEY
15.3.11 AUSTRIA
15.3.12 NORWAY
15.3.13 HUNGARY
15.3.14 LITHUANIA
15.3.15 IRELAND
15.3.16 POLAND
15.3.17 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 INDIA
15.4.4 SOUTH KOREA
15.4.5 AUSTRALIA
15.4.6 SINGAPORE
15.4.7 MALAYSIA
15.4.8 THAILAND
15.4.9 INDONESIA
15.4.10 PHILIPPINES
15.4.11 VIETNAM
15.4.12 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ARGENTINA
15.5.3 PERU
15.5.4 REST OF SOUTH AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 SAUDI ARABIA
15.6.2 SOUTH AFRICA
15.6.3 UAE
15.6.4 ISRAEL
15.6.5 EGYPT
15.6.6 KUWAIT
15.6.7 REST OF MIDDLE EAST & AFRICA
16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT
18 COMPANY PROFILE
18.1 ROQUETTE FRÈRES
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 LIGAND PHARMACEUTICALS INCORPORATED
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 TECHNOLOGY PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 WACKER CHEMIE AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 MERCK KGAA
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 CYCLOLAB
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 CAMBREX CORPORATION
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 CAYMAN CHEMICAL
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 CYCLO THERAPEUTICS, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 MIDAS PHARMA GMBH
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 TOCOPHARM CO. LIMITED
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 WELLONA PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 XI'AN DELI BIOCHEMICAL INDUSTRY CO.,LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 ZIBO QIANHUI BIOLOGICAL TECHNOLOGY CO.,LTD
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 CURRENT ANTIVIRAL DRUGS TESTED OR IN DEVELOPMENT FOR TREATMENT OF COVID-19 AND PROPOSED CYCLODEXTRINS FOR FORMULATION ENHANCEMENT
TABLE 2 PRICE OF 25G BETA-CYCLODEXTRIN
TABLE 3 PRICE OF 100G BETA-CYCLODEXTRIN
TABLE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2017-2027 (USD THOUSAND)
TABLE 5 GLOBA Β CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 6 GLOBAL 2-HYDROXYPROPYL-Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 7 GLOBAL Α CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 8 GLOBAL Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 9 GLOBAL RANDOMLY METHYLATED Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 10 GLOBAL SULFOBUTYLETHER Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 11 GLOBAL 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE 2019-2027 (USD THOUSAND)
TABLE 13 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 14 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 15 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 16 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 17 GLOBAL CYCLODEXTRINS ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 18 GLOBAL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 19 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 20 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2019-2027 (USD THOUSAND)
TABLE 23 GLOBAL SOLID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 24 GLOBAL LIQUID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2019-2027 (USD THOUSAND)
TABLE 26 GLOBAL HYDROPHILIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 27 GLOBAL HYDROPHOBIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2019-2027 (USD THOUSAND)
TABLE 29 GLOBAL DRUG SOLUBILITY AND DISSOLUTION IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 30 GLOBAL DRUG BIOAVAILABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 31 GLOBAL DRUG SAFETY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 32 GLOBAL DRUG STABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 33 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2017-2027 (USD THOUSAND)
TABLE 35 GLOBA PAIN MANAGEMENT IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 36 GLOBA CARDIOVASCULAR DISEASES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 37 GLOBA BEHAVIORAL DISORDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 38 GLOBA CANCER THERAPY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 39 GLOBA RHEUMATOID ARTHRITIS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 40 GLOBA EPILEPSY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 41 GLOBA NIEMANN PICK DISEASE TYPE C (NPC) IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 42 GLOBA OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 48 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 49 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 50 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 51 NORTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 52 NORTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 53 NORTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 54 NORTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 56 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 57 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 58 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 59 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 60 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 61 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 62 U.S. CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 63 U.S. CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 64 U.S. MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 65 U.S. AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 66 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 67 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 68 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 69 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 70 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 71 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 72 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 73 CANADA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 74 CANADA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 75 CANADA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 76 CANADA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 77 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 78 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 79 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 80 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 81 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 82 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 83 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 84 MEXICO CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 85 MEXICO CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 86 MEXICO MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 87 MEXICO AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 88 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 89 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 90 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 91 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 92 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 93 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 94 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 95 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 96 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 97 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 98 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 99 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 100 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 101 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 102 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 103 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 104 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 105 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 106 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 107 GERMANY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 108 GERMANY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 109 GERMANY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 110 GERMANY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 111 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 112 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 113 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 114 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 115 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 116 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 117 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 118 FRANCE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 119 FRANCE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 120 FRANCE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 121 FRANCE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 122 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 123 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 124 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 125 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 126 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 127 U.K CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 128 U.K CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 129 U.K CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 130 U.K CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 131 U.K MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 132 U.K AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 133 U.K CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 134 U.K CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 135 U.K CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 136 U.K CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 137 U.K CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 138 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 139 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 140 ITALY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 141 ITALY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 142 ITALY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 143 ITALY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 144 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 145 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 146 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 147 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 148 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 149 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 150 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 151 NETHERLANDS CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 152 NETHERLANDS CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 153 NETHERLANDS MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 154 NETHERLANDS AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 155 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 156 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 157 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 158 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 159 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 160 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 161 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 162 SPAIN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 163 SPAIN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 164 SPAIN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 165 SPAIN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 166 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 167 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 168 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 169 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 170 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 171 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 172 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 173 RUSSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 174 RUSSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 175 RUSSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 176 RUSSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 177 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 178 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 179 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 180 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 181 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 182 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 183 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 184 SWITZERLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 185 SWITZERLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 186 SWITZERLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 187 SWITZERLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 188 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 189 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 190 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 191 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 192 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 193 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 194 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 195 BELGIUM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 196 BELGIUM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 197 BELGIUM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 198 BELGIUM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 199 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 200 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 201 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 202 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 203 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 204 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 205 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 206 TURKEY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 207 TURKEY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 208 TURKEY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 209 TURKEY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 210 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 211 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 212 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 213 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 214 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 215 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 216 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 217 AUSTRIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 218 AUSTRIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 219 AUSTRIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 220 AUSTRIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 221 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 222 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 223 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 224 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 225 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 226 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 227 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 228 NORWAY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 229 NORWAY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 230 NORWAY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 231 NORWAY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 232 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 233 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 234 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 235 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 236 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 237 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 238 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 239 HUNGARY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 240 HUNGARY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 241 HUNGARY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 242 HUNGARY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 243 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 244 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 245 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 246 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 247 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 248 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 249 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 250 LITHUANIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 251 LITHUANIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 252 LITHUANIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 253 LITHUANIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 254 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 255 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 256 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 257 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 258 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 259 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 260 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 261 IRELAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 262 IRELAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 263 IRELAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 264 IRELAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 265 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 266 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 267 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 268 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 269 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 270 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 271 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 272 POLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 273 POLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 274 POLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 275 POLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 276 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 277 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 278 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 279 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 280 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 281 REST OF EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 282 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 283 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 284 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 285 ASIA-PACIFIC CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 286 ASIA-PACIFIC CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 287 ASIA-PACIFIC MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 288 ASIA-PACIFIC AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 289 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 290 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 291 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 292 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 293 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 294 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 295 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 296 JAPAN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 297 JAPAN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 298 JAPAN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 299 JAPAN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 300 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 301 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 302 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 303 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 304 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 305 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 306 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 307 CHINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 308 CHINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 309 CHINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 310 CHINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 311 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 312 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 313 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 314 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 315 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 316 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 317 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 318 INDIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 319 INDIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 320 INDIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 321 INDIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 322 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 323 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 324 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 325 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 326 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 327 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 328 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 329 SOUTH KOREA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 330 SOUTH KOREA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 331 SOUTH KOREA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 332 SOUTH KOREA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 333 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 334 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 335 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 336 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 337 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 338 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 339 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 340 AUSTRALIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 341 AUSTRALIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 342 AUSTRALIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 343 AUSTRALIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 344 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 345 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 346 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 347 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 348 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 349 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 350 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 351 SINGAPORE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 352 SINGAPORE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 353 SINGAPORE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 354 SINGAPORE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 355 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 356 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 357 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 358 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 359 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 360 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 361 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 362 MALAYSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 363 MALAYSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 364 MALAYSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 365 MALAYSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 366 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 367 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 368 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 369 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 370 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 371 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 372 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 373 THAILAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 374 THAILAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 375 THAILAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 376 THAILAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 377 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 378 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 379 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 380 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 381 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 382 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 383 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 384 INDONESIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 385 INDONESIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 386 INDONESIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
表387 印尼醫藥市場中兩親性環糊精的2018-2027年按結構（千美元）
表388 印尼醫藥市場中的環糊精，依性質，2018-2027（千美元）
表389 印尼醫藥市場中的環糊精，依形式，2018-2027（千美元）
表390 印尼醫藥市場中的環糊精，依應用，2018-2027（千美元）
表391 印尼醫藥市場中的環糊精，依治療領域，2018-2027（千美元）
表392 印尼醫藥市場中的環糊精，依分銷管道，2018-2027（千美元）
表393菲律賓醫藥市場環糊精，依類型，2018-2027（千美元）
表394菲律賓醫藥市場環糊精，依結構，2018-2027（千美元）
表395菲律賓醫藥市場中環糊精的環糊精關聯產品，依結構，2018-2027年（千美元）
表396菲律賓醫藥市場中環糊精結合物的市場結構，2018-2027（千美元）
表397菲律賓醫藥市場環糊精黏膜黏附藥物載體，依結構，2018-2027年（千美元）
表398菲律賓醫藥市場中兩親性環糊精的2018-2027年按結構（千美元）
表399菲律賓醫藥市場環糊精的性質，2018-2027（千美元）
表400菲律賓醫藥市場環糊精，依形式，2018-2027（千美元）
表401菲律賓醫藥市場環糊精的應用，2018-2027（千美元）
表402菲律賓醫藥市場環糊精，依治療領域，2018-2027（千美元）
表403菲律賓醫藥市場環糊精，依分銷管道，2018-2027（千美元）
表404 越南醫藥市場環糊精，依類型，2018-2027（千美元）
表405越南醫藥市場環糊精，依結構，2018-2027（千美元）
表406 越南醫藥市場中環糊精的環糊精關聯產品，依結構，2018-2027年（千美元）
表407 越南醫藥市場中環糊精結合物的市場結構，2018-2027（千美元）
表408 越南醫藥市場中環糊精黏膜黏附藥物載體，依結構，2018-2027年（千美元）
表409越南醫藥市場中兩親性環糊精的環糊精，依結構，2018-2027年（千美元）
表410越南醫藥市場環糊精的性質，2018-2027（千美元）
表411越南醫藥市場中的環糊精，依形式，2018-2027（千美元）
表412越南醫藥市場環糊精的應用，2018-2027（千美元）
表413 越南醫藥市場環糊精，依治療領域，2018-2027（千美元）
表414越南醫藥市場中的環糊精，依分銷管道，2018-2027（千美元）
表415 2018-2027年亞太其他地區環糊精醫藥市場（按類型）（千美元）
表416 南美醫藥市場中的環糊精，依國家，2018-2027（千美元）
表417 南美製藥市場中的環糊精，依類型，2018-2027（千美元）
表418南美製藥市場中的環糊精，依結構，2018-2027（千美元）
表419南美醫藥市場中環糊精的締合物，依結構，2018-2027（千美元）
表420南美醫藥市場中環糊精結合物的市場結構，2018-2027（千美元）
表421 南美製藥市場中環糊精黏膜黏附藥物載體的結構，2018-2027（千美元）
表422南美製藥市場中兩親性環糊精的環糊精，依結構，2018-2027（千美元）
表423 南美製藥市場中的環糊精，依性質，2018-2027（千美元）
表424 南美製藥市場中的環糊精，依形式，2018-2027（千美元）
表425南美醫藥市場中的環糊精，依應用，2018-2027（千美元）
表426 南美製藥市場中的環糊精，依治療領域，2018-2027（千美元）
表427南美醫藥市場中的環糊精，依分銷管道，2018-2027（千美元）
表428 2018-2027年巴西醫藥市場環糊精類型（千美元）
表429巴西醫藥市場環糊精，依結構，2018-2027（千美元）
表430巴西環糊精在醫藥市場的應用，依結構，2018-2027年（千美元）
表431 巴西醫藥市場中環糊精結合物的市場結構，2018-2027（千美元）
表432 巴西製藥市場中環糊精黏膜黏附藥物載體的結構，2018-2027（千美元）
表433 巴西醫藥市場中兩親性環糊精的2018-2027年按結構（千美元）
表434 2018-2027年巴西醫藥市場環糊精的性質（千美元）
表435 2018-2027年巴西醫藥市場環糊精的市場規模（千美元）
表436 巴西醫藥市場中的環糊精，依應用，2018-2027（千美元）
表437 2018-2027年巴西醫藥市場環糊精按治療領域（千美元）
表438巴西醫藥市場中的環糊精，依分銷管道，2018-2027（千美元）
表439 2018-2027年阿根廷醫藥市場環糊精類型（千美元）
表440阿根廷醫藥市場中的環糊精，依結構，2018-2027（千美元）
表441 阿根廷醫藥市場中環糊精的環糊精關聯產品，依結構，2018-2027年（千美元）
表442阿根廷醫藥市場中環糊精結合物的市場結構，2018-2027（千美元）
表443 阿根廷醫藥市場中環糊精黏膜黏附藥物載體的產量（千美元）
表444 阿根廷醫藥市場中兩親性環糊精的2018-2027年按結構（千美元）
表445 2018-2027年阿根廷醫藥市場環糊精的性質（千美元）
TABLE 446 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 447 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 448 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 449 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 450 PERU CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 451 PERU CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 452 PERU CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 453 PERU CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 454 PERU MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 455 PERU AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 456 PERU CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 457 PERU CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 458 PERU CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 459 PERU CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 460 PERU CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 461 REST OF SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 462 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 463 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 464 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 465 MIDDLE EAST & AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 466 MIDDLE EAST & AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 467 MIDDLE EAST & AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 468 MIDDLE EAST & AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 469 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 470 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 471 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 472 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 473 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 474 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 475 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 476 SAUDI ARABIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 477 SAUDI ARABIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 478 SAUDI ARABIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 479 SAUDI ARABIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 480 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 481 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 482 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 483 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 484 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 485 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 486 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 487 SOUTH AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 488 SOUTH AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 489 SOUTH AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 490 SOUTH AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 491 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 492 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 493 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 494 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 495 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 496 UAE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 497 UAE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 498 UAE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 499 UAE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 500 UAE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 501 UAE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 502 UAE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 503 UAE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 504 UAE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 505 UAE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 506 UAE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 507 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 508 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 509 ISRAEL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 510 ISRAEL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 511 ISRAEL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 512 ISRAEL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 513 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 514 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 515 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 516 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 517 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 518 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 519 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 520 EGYPT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 521 EGYPT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 522 EGYPT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 523 EGYPT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 524 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 525 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 526 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 527 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 528 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 529 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 530 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 531 KUWAIT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 532 KUWAIT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 533 KUWAIT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
表534 科威特醫藥市場中兩親性環糊精的含量，依結構，2018-2027年（千美元）
表535 科威特醫藥市場中的環糊精，依性質，2018-2027（千美元）
表536 科威特環糊精在醫藥市場的應用，依形式，2018-2027（千元）
表537 科威特環糊精在醫藥市場的應用，2018-2027（千元）
表538 科威特環糊精在醫藥市場的治療領域，2018-2027（千美元）
表539科威特環糊精在醫藥市場的應用，依分銷管道，2018-2027（千美元）
表540 中東和非洲其他地區醫藥市場環糊精需求量（按類型），2018-2027（千美元）
图片列表
圖表列表
圖 1 全球醫藥市場中的環糊精：細分
圖 2 全球醫藥市場中的環糊精：數據三角測量
圖 3 全球醫藥市場中的環糊精：DROC 分析
圖 4 全球醫藥市場中的環糊精：全球與區域市場分析
圖5 全球醫藥市場中的環糊精：公司研究分析
圖 6 全球醫藥市場中的環糊精：多變量建模
圖 7 全球環糊精在醫藥市場：市場應用覆蓋範圍
圖 8 全球醫藥市場中的環糊精：訪談人口統計
圖 9 全球環糊精在醫藥市場：DBMR 市場地位網格
圖10 全球醫藥市場環糊精：供應商份額分析
圖 11 全球醫藥市場中的環糊精：細分
圖12 預計2020年至2027年預測期間北美將主導全球醫藥環糊精市場
圖 13 提高水溶性差的藥物的生物利用度和提高藥物穩定性是推動 2020 年至 2027 年預測期內全球環糊精在製藥市場發展的主要因素
圖 14B 環糊精部分預計在 2020 年和 2027 年佔據全球環糊精醫藥市場的最大份額
圖 15 2020 年至 2027 年預測期間內，亞太地區是全球環糊精醫藥市場中成長最快的市場
圖16 全球環糊精在醫藥市場、管道分析
圖 17 全球環糊精在醫藥市場的驅動因素、限制因素、機會與挑戰
圖 18 全球醫藥市場中的環糊精：依類型，2019 年
圖 19 全球醫藥市場中的環糊精：按類型，2019-2027 年（千美元）
圖 20 全球醫藥市場中的環糊精：按類型、複合年增長率（2020-2027）
圖21 全球醫藥市場中的環糊精：依類型、生命線曲線
圖 22 全球醫藥市場中的環糊精：依結構，2019 年
圖 23 全球醫藥市場中的環糊精：依結構，2019-2027 年（千美元）
圖 24 全球醫藥市場中的環糊精：依結構、複合年增長率（2020-2027）
圖25 全球醫藥市場中的環糊精：依結構、生命線曲線
圖 26 全球醫藥市場中的環糊精：依形式，2019 年
圖 27 全球醫藥市場中的環糊精：依形式，2019-2027 年（千美元）
圖 28 全球醫藥市場中的環糊精：依形式、複合年增長率（2020-2027）
圖 29 全球醫藥市場中的環糊精：依形式、生命線曲線
圖 30 全球醫藥市場中的環糊精：依性質，2019 年
圖 31 全球製藥市場中的環糊精：依性質，2019-2027 年（千美元）
圖 32 全球醫藥市場中的環糊精：依性質、複合年增長率（2020-2027）
圖 33 全球醫藥市場中的環糊精：依性質、生命線曲線
圖 34 全球醫藥市場中的環糊精：依應用，2019 年
圖35 全球醫藥市場中的環糊精：按應用，2019-2027（千美元）
圖 36 全球醫藥市場中的環糊精：依應用，複合年增長率（2020-2027）
圖37 全球醫藥市場中的環糊精：依分銷管道、生命線曲線
圖 38 全球醫藥市場中的環糊精：依治療領域，2019 年
圖39 全球醫藥市場中的環糊精：依治療領域，2019-2027年（千美元）
圖 40 全球醫藥市場中的環糊精：依治療領域，複合年增長率（2020-2027）
圖41 全球醫藥市場中的環糊精：依治療領域、生命線曲線
圖 42 全球醫藥市場環糊精：按分銷管道，2019 年
圖 43 全球醫藥市場中的環糊精：按分銷管道，2019-2027 年（千美元）
圖 44 全球醫藥市場中的環糊精：依分銷管道，複合年增長率（2020-2027）
圖45 全球醫藥市場中的環糊精：依分銷管道、生命線曲線
圖 46 全球醫藥市場環糊精：快照（2019 年）
圖 47 全球醫藥市場中的環糊精：按地區（2019）
圖 48 全球醫藥市場中的環糊精：按地區（2020 年和 2027 年）
圖 49 全球醫藥市場中的環糊精：按地區（2019 年和 2027 年）
圖 50 全球醫藥市場中的環糊精：依類型（2020-2027）
圖 51 北美醫藥市場環糊精：快照（2019 年）
圖52 北美醫藥市場環糊精：依國家（2019年）
圖 53 北美醫藥市場中的環糊精：依國家（2020 年和 2027 年）
圖 54 北美醫藥市場環糊精：依國家（2019 年及 2027 年）
圖 55 北美醫藥市場環糊精：依類型（2020-2027）
圖 56 歐洲醫藥市場環糊精：快照（2019 年）
圖 57 歐洲醫藥市場環糊精：依國家（2019 年）
圖 58 歐洲醫藥市場中的環糊精：依國家（2020 年和 2027 年）
圖 59 歐洲醫藥市場環糊精：依國家（2019 年及 2027 年）
圖 60 歐洲醫藥市場環糊精：依類型（2020-2027）
圖 61 亞太地區環糊精在醫藥市場的概況（2019 年）
圖62 亞太地區醫藥市場環糊精：依國家（2019年）
圖 63 亞太地區醫藥市場中的環糊精：依國家（2020 年和 2027 年）
圖 64 亞太地區醫藥市場環糊精：依國家（2019 年和 2027 年）
圖 65 亞太醫藥市場中的環糊精：依類型（2020-2027）
FIGURE 66 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 67 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 68 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 69 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 70 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 71 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 72 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 73 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 74 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 75 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 76 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 77 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 78 EUROPE CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 79 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKETMARKET: COMPANY SHARE 2019 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
